Prophylactic Effect of Probiotic Streptococcus Salivarius eK12 Against Recurrent Streptococcus Pyogenes Pharyngotonsillitis Infection in Pediatrics
Study to Investigate the Prophylactic Effect of Probiotic Streptococcus Salivarius eK12 Supplementation Against Recurrent Streptococcus Pyogenes (GAS) Bacterial Pharyngotonsillitis in Children: A Randomized, Double-blind Controlled Clinical Trial
Liaquat University of Medical & Health Sciences
60 participants
Dec 1, 2025
INTERVENTIONAL
Conditions
Summary
Recurrent Group A Streptococcus (GAS) infections, primarily presenting as strep throat, are a significant health concern in pediatric populations, leading to symptoms like sore throat, fever, and swollen lymph nodes. GAS is highly contagious and can spread easily among children in close-contact environments like schools and daycare centers, often resulting in frequent re-infections. Managing these recurrent infections typically requires antibiotics, but reliance on antibiotics carries risks, including resistance development, gut microbiota disruption, and various side effects. Probiotic therapy, particularly with Streptococcus salivarius K12, has shown promise as a preventive approach, utilizing competitive exclusion and antimicrobial production to inhibit GAS growth in the oral cavity. Recent studies have advanced this with the development of S. salivarius eK12, a re-engineered strain that enhances efficacy against GAS by preventing the survival-promoting interactions between the probiotic and pathogenic bacteria. This modified strain, now registered as Bactoblis® EVOL in Italy (EU), holds potential as an effective version to reduce the incidence and severity of GAS infections without the drawbacks of antibiotic therapy.
Eligibility
Inclusion Criteria5
- Children aged 3-10 years.
- Recent history of documented recurrent episodes of Streptococcus pyogenes pharyngo- tonsillitis infection in the last 6 months, or 4 or more episodes in the last 12 months (S.
- pyogenes infection being defined as: McIsaac score with clinical score ≥ 2 plus confirmation of S. pyogenes presence with rapid throat swab (RAD) method or McIsaac score =5.
- Willingness to comply with the study protocol and attend scheduled follow-up visits.
- Written informed consent obtained from the parent or legal guardian.
Exclusion Criteria11
- Children with known allergies or hypersensitivity to probiotics or any components of the study product.
- Current use of antibiotics or within the past 30 days.
- Used oral colonizing probiotics in the last 6 months.
- Presence of severe underlying medical conditions affecting the immune system or gastrointestinal tract.
- Participation in other clinical trials involving investigational drugs or interventions.
- Inability to adhere to the study requirements due to logistical or social reasons.
- History of rheumatic disorders, bronchospasm, severe asthma, or allergy requiring corticosteroids.
- Past tonsillectomy or an indication for adeno-tonsillectomy; or severe respiratory or systemic disorders
- Individuals immunocompromised or had a condition favouring recurrent Acute Otitis Media (AOM), including severe atopy, acquired or congenital immunodeficiency, cleft palate, craniofacial abnormalities, obstructive adenoids, a chronically ruptured eardrum, sleep apnoea, or tympanostomy tubes
- Children undergoing current pharmacological therapies to prevent recurrent respiratory infections.
- Any other medical condition or circumstance that, in the investigator's judgment, would compromise the safety of the participant or the integrity of the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06370208